Jacobs Levy Equity Management, Inc Lyell Immunopharma, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q1 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 558,979 shares of LYEL stock, worth $4.86 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
558,979
Previous 1,385,301
59.65%
Holding current value
$4.86 Million
Previous $886,000
66.03%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding LYEL
# of Institutions
117Shares Held
175MCall Options Held
2.9KPut Options Held
6K-
Mwg Management Ltd. Washington, DC20.2MShares$175 Million18.54% of portfolio
-
Foresite Capital Management Iv, LLC Larkspur, CA16MShares$139 Million9.84% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$131 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$131 Million9.84% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$117 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $2.15B
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...